Replication-defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2005 Apr 29

PMID 15858035

Citations 68

Authors

Sampa Santra

Michael S Seaman

Ling Xu

Dan H Barouch

Carol I Lord

Michelle A Lifton

Darci A Gorgone

Kristin R Beaudry

Krisha Svehla

Brent Welcher

Bimal K Chakrabarti

Yue Huang

Zhi-Yong Yang

John R Mascola

Gary J Nabel

Norman L Letvin

Affiliations

Soon will be listed here.

Abstract

The magnitude and durability of immune responses induced by replication-defective adenovirus serotype 5 (ADV5) vector-based vaccines were evaluated in the simian-human immunodeficiency virus/rhesus monkey model. A single inoculation of recombinant ADV5 vector constructs induced cellular and humoral immunity, but the rapid generation of neutralizing anti-Ad5 antibodies limited the immunity induced by repeated vector administration. The magnitude and durability of the immune responses elicited by these vaccines were greater when they were delivered as boosting immunogens in plasmid DNA-primed monkeys than when they were used as single-modality immunogens. Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection.

Citing Articles

The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.

Wallace R, Bliss C, Parker A Viruses. 2024; 16(6).

PMID: 38932265 PMC: 11209478. DOI: 10.3390/v16060973.

Viral Vector-Based Gene Therapy.

Li X, Le Y, Zhang Z, Nian X, Liu B, Yang X Int J Mol Sci. 2023; 24(9).

PMID: 37175441 PMC: 10177981. DOI: 10.3390/ijms24097736.

Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination.

Byazrova M, Astakhova E, Minnegalieva A, Sukhova M, Mikhailov A, Prilipov A NPJ Vaccines. 2022; 7(1):145.

PMID: 36379998 PMC: 9665038. DOI: 10.1038/s41541-022-00566-x.

Adenovirus Vectors: Excellent Tools for Vaccine Development.

Chang J Immune Netw. 2021; 21(1):e6.

PMID: 33728099 PMC: 7937504. DOI: 10.4110/in.2021.21.e6.

Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer.

Adamaki M, Zoumpourlis V Cancers (Basel). 2021; 13(2).

PMID: 33419051 PMC: 7825410. DOI: 10.3390/cancers13020173.

References

Egan M, Charini W, Kuroda M, Schmitz J, Racz P, Tenner-Racz K . Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J Virol. 2000; 74(16):7485-95. PMC: 112269. DOI: 10.1128/jvi.74.16.7485-7495.2000. View

Sprangers M, Lakhai W, Koudstaal W, Verhoeven M, Koel B, Vogels R . Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003; 41(11):5046-52. PMC: 262545. DOI: 10.1128/JCM.41.11.5046-5052.2003. View

Sullivan N, Sanchez A, Rollin P, Yang Z, Nabel G . Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000; 408(6812):605-9. DOI: 10.1038/35046108. View

Amara R, Villinger F, Altman J, Lydy S, ONeil S, Staprans S . Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001; 292(5514):69-74. DOI: 10.1126/science.1058915. View

Huang Y, Kong W, Nabel G . Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol. 2001; 75(10):4947-51. PMC: 114253. DOI: 10.1128/JVI.75.10.4947-4951.2001. View

Rose N, Marx P, Luckay A, Nixon D, Moretto W, Donahoe S . An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 2001; 106(5):539-49. DOI: 10.1016/s0092-8674(01)00482-2. View

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

Letvin N, Barouch D, Montefiori D . Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol. 2002; 20:73-99. DOI: 10.1146/annurev.immunol.20.081501.094854. View

Chakrabarti B, Kong W, Yang Z, Friborg J, Ling X, King S . Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol. 2002; 76(11):5357-68. PMC: 137015. DOI: 10.1128/jvi.76.11.5357-5368.2002. View

10.

Casimiro D, Chen L, Fu T, Evans R, Caulfield M, Davies M . Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003; 77(11):6305-13. PMC: 154996. DOI: 10.1128/jvi.77.11.6305-6313.2003. View

11.

Barouch D, McKay P, Sumida S, Santra S, Jackson S, Gorgone D . Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol. 2003; 77(16):8729-35. PMC: 167238. DOI: 10.1128/jvi.77.16.8729-8735.2003. View

12.

Yang Z, Chakrabarti B, Xu L, Welcher B, Kong W, Leung K . Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J Virol. 2004; 78(8):4029-36. PMC: 374252. DOI: 10.1128/jvi.78.8.4029-4036.2004. View

13.

Barouch D, Pau M, Custers J, Koudstaal W, Kostense S, Havenga M . Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004; 172(10):6290-7. DOI: 10.4049/jimmunol.172.10.6290. View

14.

Letvin N, Huang Y, Chakrabarti B, Xu L, Seaman M, Beaudry K . Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol. 2004; 78(14):7490-7. PMC: 434100. DOI: 10.1128/JVI.78.14.7490-7497.2004. View

15.

Santra S, Barouch D, Korioth-Schmitz B, Lord C, Krivulka G, Yu F . Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci U S A. 2004; 101(30):11088-93. PMC: 503745. DOI: 10.1073/pnas.0401954101. View

16.

Hirsch V, Fuerst T, Sutter G, Carroll M, Yang L, Goldstein S . Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol. 1996; 70(6):3741-52. PMC: 190250. DOI: 10.1128/JVI.70.6.3741-3752.1996. View

17.

Egan M, Kuroda M, Voss G, Schmitz J, Charini W, Lord C . Use of major histocompatibility complex class I/peptide/beta2M tetramers to quantitate CD8(+) cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys. J Virol. 1999; 73(7):5466-72. PMC: 112603. DOI: 10.1128/JVI.73.7.5466-5472.1999. View

18.

Barouch D, Santra S, Schmitz J, Kuroda M, Fu T, Wagner W . Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000; 290(5491):486-92. DOI: 10.1126/science.290.5491.486. View